310 related articles for article (PubMed ID: 12721666)
21. Celecoxib versus a non-selective NSAID plus proton-pump inhibitor: what are the considerations?
Chen JT; Pucino F; Resman-Targoff BH
J Pain Palliat Care Pharmacother; 2006; 20(4):11-32. PubMed ID: 17182503
[TBL] [Abstract][Full Text] [Related]
22. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
23. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
[TBL] [Abstract][Full Text] [Related]
24. Hospitalization for gastrointestinal bleeding associated with non-steroidal anti-inflammatory drugs among elderly patients using low-dose aspirin: a retrospective cohort study.
Rahme E; Bardou M; Dasgupta K; Toubouti Y; Ghosn J; Barkun AN
Rheumatology (Oxford); 2007 Feb; 46(2):265-72. PubMed ID: 16844699
[TBL] [Abstract][Full Text] [Related]
25. Early presentation with angioedema and urticaria in cross-reactive hypersensitivity to nonsteroidal antiinflammatory drugs among young, Asian, atopic children.
Kidon MI; Kang LW; Chin CW; Hoon LS; See Y; Goh A; Lin JT; Chay OM
Pediatrics; 2005 Nov; 116(5):e675-80. PubMed ID: 16230465
[TBL] [Abstract][Full Text] [Related]
26. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema.
Colanardi MC; Nettis E; Traetta P; Daprile C; Fitto C; Aloia AM; Di Leo E; Ferrannini A; Vacca A
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):82-5. PubMed ID: 18254487
[TBL] [Abstract][Full Text] [Related]
27. Atopy is a risk factor for non-steroidal anti-inflammatory drug sensitivity.
Sánchez-Borges M; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2000 Jan; 84(1):101-6. PubMed ID: 10674573
[TBL] [Abstract][Full Text] [Related]
28. Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Aug; 95(2):154-8. PubMed ID: 16136765
[TBL] [Abstract][Full Text] [Related]
29. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
Maetzel A; Krahn M; Naglie G
Arthritis Rheum; 2003 Jun; 49(3):283-92. PubMed ID: 12794781
[TBL] [Abstract][Full Text] [Related]
30. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
[TBL] [Abstract][Full Text] [Related]
31. Safety of celecoxib in patients with adverse reactions to nimesulide.
Liccardi G; D'Amato G; Canonica GW; Lobefalo G; Noschese P; Piccolo A; Salzillo A; Passalacqua G
Allergy; 2005 May; 60(5):708-9. PubMed ID: 15813826
[No Abstract] [Full Text] [Related]
32. Tolerability of selective cyclooxygenase inhibitor, celecoxib, in patients with analgesic intolerance.
Celik G; Paşaoğlu G; Bavbek S; Abadoğlu O; Dursun B; Mungan D; Misirligil Z
J Asthma; 2005 Mar; 42(2):127-31. PubMed ID: 15871445
[TBL] [Abstract][Full Text] [Related]
33. Factors associated with celecoxib and rofecoxib utilization.
Rawson NS; Nourjah P; Grosser SC; Graham DJ
Ann Pharmacother; 2005 Apr; 39(4):597-602. PubMed ID: 15755796
[TBL] [Abstract][Full Text] [Related]
34. Biochemical and clinical evidence that aspirin-intolerant asthmatic subjects tolerate the cyclooxygenase 2-selective analgetic drug celecoxib.
Gyllfors P; Bochenek G; Overholt J; Drupka D; Kumlin M; Sheller J; Nizankowska E; Isakson PC; Mejza F; Lefkowith JB; Dahlén SE; Szczeklik A; Murray JJ; Dahlén B
J Allergy Clin Immunol; 2003 May; 111(5):1116-21. PubMed ID: 12743579
[TBL] [Abstract][Full Text] [Related]
35. The hepatic safety and tolerability of the cyclooxygenase-2 selective NSAID celecoxib: pooled analysis of 41 randomized controlled trials.
Soni P; Shell B; Cawkwell G; Li C; Ma H
Curr Med Res Opin; 2009 Aug; 25(8):1841-51. PubMed ID: 19530981
[TBL] [Abstract][Full Text] [Related]
36. Utilization of non-steroidal anti-inflammatory drugs in Quebec: adherence to the Canadian consensus on prescription guidelines.
Moride Y; Ducruet T; Boivin JF; Lavoie F; Rochon S
Can J Clin Pharmacol; 2005; 12(2):e201-11. PubMed ID: 15998959
[TBL] [Abstract][Full Text] [Related]
37. Cardiovascular events associated with the use of four nonselective NSAIDs (etodolac, nabumetone, ibuprofen, or naproxen) versus a cyclooxygenase-2 inhibitor (celecoxib): a population-based analysis in Taiwanese adults.
Huang WF; Hsiao FY; Wen YW; Tsai YW
Clin Ther; 2006 Nov; 28(11):1827-36. PubMed ID: 17213003
[TBL] [Abstract][Full Text] [Related]
38. Risk of hospitalization for myocardial infarction among users of rofecoxib, celecoxib, and other NSAIDs: a population-based case-control study.
Johnsen SP; Larsson H; Tarone RE; McLaughlin JK; Nørgård B; Friis S; Sørensen HT
Arch Intern Med; 2005 May; 165(9):978-84. PubMed ID: 15883235
[TBL] [Abstract][Full Text] [Related]
39. [Urticaria--angioedema induced by non-steroidal anti-inflammatory analgesics].
Díez Gómez ML; Alvarez Cuesta E; Hinojosa Macías M; García Cañadillas F; Alcover Sánchez R
Allergol Immunopathol (Madr); 1984; 12(3):179-88. PubMed ID: 6332509
[TBL] [Abstract][Full Text] [Related]
40. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults.
Solomon DH; Schneeweiss S; Glynn RJ; Kiyota Y; Levin R; Mogun H; Avorn J
Circulation; 2004 May; 109(17):2068-73. PubMed ID: 15096449
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
